Neurotrope (NASDAQ:NTRP) Upgraded at ValuEngine

ValuEngine upgraded shares of Neurotrope (NASDAQ:NTRP) from a hold rating to a buy rating in a research note issued to investors on Thursday morning, ValuEngine reports.

Separately, Janney Montgomery Scott assumed coverage on shares of Neurotrope in a report on Tuesday, June 18th. They issued a buy rating and a $14.00 target price for the company.

Shares of Neurotrope stock remained flat at $$4.96 during trading on Thursday. 86,268 shares of the stock traded hands, compared to its average volume of 120,454. The firm’s 50 day moving average price is $6.64. The firm has a market cap of $64.22 million, a price-to-earnings ratio of -3.62 and a beta of 2.44. Neurotrope has a 12-month low of $3.33 and a 12-month high of $10.50.

Neurotrope (NASDAQ:NTRP) last released its earnings results on Thursday, May 9th. The company reported ($0.36) earnings per share (EPS) for the quarter. As a group, equities analysts anticipate that Neurotrope will post -1.56 earnings per share for the current year.

An institutional investor recently bought a new position in Neurotrope stock. Raymond James & Associates bought a new position in Neurotrope Inc (NASDAQ:NTRP) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 11,823 shares of the company’s stock, valued at approximately $42,000. Raymond James & Associates owned about 0.15% of Neurotrope at the end of the most recent quarter. Institutional investors own 13.81% of the company’s stock.

About Neurotrope

Neurotrope, Inc, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases.

Recommended Story: Insider Trading – What You Need to Know

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Neurotrope Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurotrope and related companies with's FREE daily email newsletter.